Trastuzumab plus capecitabine and docetaxel as first-line therapy for HER2-positive metastatic breast cancer: Phase II results

Anticancer Research

Volumn 30, Issue 7, 2010, Pages 3051-3054

  Michalaki, Vasiliki ^a   Fotiou, Stylianos ^a   Gennatas, Spyridon ^a   Gennatas, Constantine ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

Combination; Metastatic breast cancer; Pretreated; Trastuzumab

Indexed keywords

CAPECITABINE; CORTICOSTEROID; DEXAMETHASONE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; TRASTUZUMAB;

ADULT; AGED; ALLERGIC REACTION; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; GASTROINTESTINAL TOXICITY; GRANULOCYTOPENIA; HAND FOOT SYNDROME; HEART LEFT VENTRICLE FAILURE; HUMAN; LOADING DRUG DOSE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; STOMATITIS; SURVIVAL TIME; TREATMENT RESPONSE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; PROSPECTIVE STUDIES; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TAXOIDS;

EID: 77955805622     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A and McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER2/neu oncogene. Science 235: 177-182, 1987.
2. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J and Ullrich A: Studies of the HER2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707-712, 1989.
3. Ravdin PM and Chamness GC: The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: A paradigm for the development of other macromolecular markers - A review. Gene 159: 19-27, 1995.
4. Pegram MD, Lopez A, Konecny G and Slamon DJ: Trastuzumab and chemotherapeutics: Drug interactions and synergies. Semin Oncol 27: 21-25, 2000. (Pubitemid 32172252)
5. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ and Press M: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20: 719-726, 2002.
6. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J and Norton L: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783-792, 2001.
7. Krasinska L and Jassem J: Taxanes in the treatment of advanced breast cancer. J Oncol 53: 176-184, 2003. (Pubitemid 36604185)
8. Bullock K and Blackwell K: Clinical efficacy of taxane-trastuzumab combination regimens for HER-2-positive metastatic breast cancer. Oncologist 5: 515-525, 2008. (Pubitemid 351872869)
9. Montemurro F, Choa G, Faggiuolo R, Sperti E, Capaldi A, Donadio M, Minischetti M, Salomone A, Vietti-Ramus G, Alabiso O and Aglietta M: Safety and activity of docetaxel and trastuzumab in HER2 overexpressing breast cancer: A pilot phase II study. Am J Clin Oncol 26: 95-97, 2003.
10. Raff JP, Rajdev L, Malik U, Novik Y, Manalo JM, Negassa A, Hopkins U, Sarta C and Sparano JA: Phase II study of weekly docetaxel alone or in combination with trastuzumab in patients with metastatic breast cancer. Clin Breast Cancer 4: 420-427 2004. (Pubitemid 38443465)
11. O'Shaughnessy J: Capecitabine and docetaxel in advanced breast cancer: analyses of a phase III comparative trial. Oncology (Williston Park) Suppl 12: 17-22, 2002.
12. Michalaki V, Gennatas S and Gennatas K: Low-dose capecitabine plus docetaxel as first-line therapy for metastatic breast cancer: phase II results. Anticancer Drugs 3: 204-207, 2009.
13. Baselga J: Herceptin alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer: Pivotal trials. Oncology 61(suppl 2): 14-21, 2001. (Pubitemid 33033420)
14. Robert N, Leyland-Jones B, Asmar L, Belt R, Ilegbodu D, Loesch D, Raju R, Valentine E, Sayre R, Cobleigh M, Albain K, McCullough C, Fuchs L and Slamon D: Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 24: 2786-2792, 2006
15. Pienkowski T, Pegram M and Forbes J: BCIRG 007: First overall survival analysis of randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin as first line therapy in HER2 amplified metastatic breast cancer (MBC). EJC (suppl 5; abstr 2098), 2007.
16. Wardley A, Pivot X, Morales-Vasquez F, Luis M, Dias Z, Gaui L, Douglas O, Jassem J, Barton C, Button P, Hersberger V and Torres A: Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer. J Clin Oncol 28: 976-983, 2010.
17. Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M, Chan S, Grimes D, Antón A, Lluch A, Kennedy J, O'Byrne K, Conte P, Green M, Ward C, Mayne K and Extra JM: Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: The M77001 study group. J Clin Oncol 23: 4265-4274, 2005.
18. Perez EA and Rodeheffer R: Clinical cardiac tolerability of trastuzumab. J Clin Oncol 22: 322-329, 2004.